OSE Immunotherapeutics (LSE:0RAD) - 주가, 뉴스 및 분석

0RAD 주식 개요

임상 단계의 생명공학 회사인 OSE Immunotherapeutics SA는 프랑스 및 전 세계에서 면역 종양학 및 면역 염증 분야의 면역 치료제를 개발하는 회사입니다.

0RAD 기본 분석
눈송이 점수
가치 평가	3/6
미래 성장	0/6
과거 실적	4/6
재무 상태	5/6
배당금	0/6

보상

주가수익률( 4.7 x)이 UK 시장( 16.3 x)보다 낮습니다.

올해부터 흑자전환

분석가들은 주가가 27.4% 상승할 것이라는 데 동의합니다.

위험 분석

수익은 향후 3년간 연평균 72.5% 씩 감소할 것으로 예상됩니다.

최근 3개월간 주가 변동폭 심해

지난 1년 동안 주주가 희석되었습니다.

OSE Immunotherapeutics SA 경쟁사

Bioventix

AIM:BVXP

UK£194.4m

Genus

LSE:GNS

UK£1.3b

hVIVO

AIM:HVO

UK£189.1m

Animalcare Group

AIM:ANCR

UK£141.3m

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 OSE Immunotherapeutics
과거 주가
현재 주가	€10.46
52주 최고치	€11.22
52주 최저치	€3.25
베타	0.90
11개월 변경	19.13%
3개월 변경 사항	47.53%
1년 변경 사항	139.90%
33년 변화	16.90%
5년 변화	n/a
IPO 이후 변화	74.33%

최근 뉴스 및 업데이트

Recent updates

주주 수익률

	0RAD	GB Biotechs	GB 마켓
7D	3.6%	-2.7%	-0.6%
1Y	139.9%	-16.1%	8.8%

수익률 대 산업: 0RAD 지난 1년 동안 -16.1 %를 반환한 UK Biotechs 산업을 초과했습니다.

수익률 대 시장: 0RAD 지난 1년 동안 8.8 %를 반환한 UK 시장을 초과했습니다.

가격 변동성

Is 0RAD's price volatile compared to industry and market?
0RAD volatility
0RAD Average Weekly Movement	11.3%
Biotechs Industry Average Movement	8.0%
Market Average Movement	4.6%
10% most volatile stocks in GB Market	9.5%
10% least volatile stocks in GB Market	2.5%

안정적인 주가: 0RAD 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: 0RAD 의 주간 변동성( 11% )은 지난 1년 동안 안정적이었지만 여전히 UK 의 75%보다 높습니다. 주식.

회사 소개

설립	직원	CEO	웹사이트
2012	52	Nicolas Poirier	www.ose-immuno.com

임상 단계의 생명공학 회사인 OSE Immunotherapeutics SA는 프랑스 및 국제적으로 면역 종양학 및 면역 염증 분야의 면역 치료제를 개발합니다. 주요 제품으로는 비소세포폐암 치료제로 임상 3상을 진행 중인 테도피와 췌장암 및 난소암 임상 2상 중인 테도피, 진행성 고형암 또는 림프종 환자를 대상으로 임상 1상/2상 중인 OSE-279가 있습니다; 궤양성 대장염 및 쇼그렌 증후군 치료를 위한 임상 2상 중인 인간화 단일클론 항체 OSE-127, 류마티스 관절염 치료를 위한 임상 1상 중인 FR104. 또한 고형 종양 치료를 위한 임상 1상 시험 중인 BI 765063, 만성 염증 해결을 위한 ChemR23 작용제 항체인 OSE-230, 면역항암제 치료 표적이자 확인된 단일 클론 항체 길항제인 CLEC-1, 암이 발생하는 1차 및 2차 내성 메커니즘에 대항하기 위해 PD-1을 표적으로 하는 새로운 이중 특이적 체크포인트 억제제 플랫폼인 BiCKI를 개발 중입니다.

OSE Immunotherapeutics SA 기본 사항 요약

OSE Immunotherapeutics 의 수익과 매출은 시가총액과 어떻게 비교하나요?
0RAD 기본 통계
시가총액	€215.79m
수익(TTM)	€46.03m
수익(TTM)	€83.44m

4.7x

P/E 비율

2.6x

P/S 비율

0RAD 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
0RAD 손익 계산서(TTM)
수익	€83.44m
수익 비용	€0
총 이익	€83.44m
기타 비용	€37.41m
수익	€46.03m

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

n/a

주당 순이익(EPS)	2.12
총 마진	100.00%
순이익 마진	55.17%
부채/자본 비율	49.6%

0RAD 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

0RAD 주식 개요

보상

위험 분석

OSE Immunotherapeutics SA 경쟁사

AIM:BVXP

UK£194.4m

LSE:GNS

UK£1.3b

AIM:HVO

UK£189.1m

AIM:ANCR

UK£141.3m

가격 내역 및 성능

최근 뉴스 및 업데이트

Investor sentiment improves as stock rises 18%

First half 2024 earnings released: EPS: €2.63 (vs €0.64 loss in 1H 2023)

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

OSE Immunotherapeutics Presents Preclinical Data on Mrna Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders At the Focis Annual Meeting, San Francisco

Forecast breakeven date moved forward to 2024

Recent updates

Investor sentiment improves as stock rises 18%

First half 2024 earnings released: EPS: €2.63 (vs €0.64 loss in 1H 2023)

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

OSE Immunotherapeutics Presents Preclinical Data on Mrna Therapeutic Platform for the Treatment of Inflammatory and Autoimmune Disorders At the Focis Annual Meeting, San Francisco

Forecast breakeven date moved forward to 2024

OSE Immunotherapeutics SA, Annual General Meeting, Jun 19, 2024

Full year 2023 earnings released: €1.18 loss per share (vs €0.96 loss in FY 2022)

OSE Immunotherapeutics Provides Update on Clinical Results With OSE-279 in Advanced Solid Tumors

New minor risk - Share price stability

New minor risk - Shareholder dilution

OSE Immunotherapeutics SA and Nantes University Hospital Presents Positive Interim Data Analysis from the FIRsT Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplant

Ose Immunotherapeutics Sa Announces First Clinical Results for Bi 770371, A Novel Anti-Sirpa Monoclonal Antibody

First half 2023 earnings released: €0.64 loss per share (vs €0.11 loss in 1H 2022)

Forecast breakeven date moved forward to 2024

New major risk - Financial position

High number of new directors

OSE Immunotherapeutics SA Announces Publication in Frontiers in Immunology on Ose-230, Its Novel Agonist Therapy in Chronic Inflammation

OSE Immunotherapeutics and Nantes University Hospital Announce Completion of Patient Enrollment in the FIRsT Clinical Trial, a Phase 1/2 Study Evaluating FR104/VEL-101 Immunotherapy in Renal Transplantation

OSE Immunotherapeutics SA Announces for Lusvertikimab, its Anti-IL-7 Receptor Antagonist

High number of new directors

OSE Immunotherapeutics SA Appoints Eric Leire as A New Independent Director and Anne-Laure Autret-Cornet as Director

OSE Immunotherapeutics SA Presents Clinical Abstracts on Tedopi at the ASCO 2023 Annual Meeting

OSE Immunotherapeutics SA, Annual General Meeting, Jun 22, 2023

OSE Immunotherapeutics and GERCOR Oncology Clinician Group Announces Completion of Patient Enrollment in TEDOPaM Phase 2 Clinical Trial with Tedopi in Advanced Pancreatic Cancer

Forecast to breakeven in 2025

Full year 2022 earnings released: €0.96 loss per share (vs €0.93 loss in FY 2021)

OSE Immunotherapeutics SA Provides Regulatory Update on Tedopi®, a Cancer Vaccine at a Late-Stage Clinical Development in Lung Cancer After Failure to Immunotherapies

OSE Immunotherapeutics SA Announces First Patient Dosed with Anti-PD1 Monoclonal Antibody OSE-279 in Phase 1/2 Clinical Trial in Advanced Solid Tumors or Lymphomas

OSE Immunotherapeutics SA Announces Latest Preclinical Efficacy Data on its Anti-IL-7 Receptor Antagonist OSE-127 in Acute Lymphoblastic Leukemia at the 2022 American Society of Hematology (ASH) Annual Meeting

Ose Immunotherapeutics Announces Publication of Peer-Reviewed Data on Clec-1

Servier and OSE Immunotherapeutics Announce Completion of Patient Enrollment in the Phase 2a Clinical Trial of OSE-127/S95011 in Primary Sjögren’s Syndrome

OSE Immunotherapeutics SA Updates on Tedopi®, Cancer Vaccine as Potential New Standard of Care in Non-Small Cell Lung Cancer After Failure to Immunotherapies

OSE Immunotherapeutics SA Appoints Nicolas Poirier as Chief Executive Officer

First half 2022 earnings released: €0.11 loss per share (vs €0.64 loss in 1H 2021)

Ose Immunotherapeutics to Present New Data on Tedopi® from Phase 3 Clinical Trial in Patients with Advanced Non-Small Cell Lung Cancer After Failure to Immune Checkpoint Inhibitors At Esmo Congress 2022

Ose Immunotherapeutics to Present New Data on Tedopi® from Phase 3 Clinical Trial in Patients with Advanced Non-Small Cell Lung Cancer After Failure to Immune Checkpoint Inhibitors At Esmo Congress 2022

OSE Immunotherapeutics SA Appoints Alexis Vandier as Chief Executive Officer

OSE Immunotherapeutics SA, Annual General Meeting, Jun 23, 2022

OSE Immunotherapeutics SA Appoints its International Scientific Advisory Board

Boehringer Ingelheim and OSE Immunotherapeutics Announce First Patient Dosed in a Phase 1 Expansion Trial of SIRPa Antagonist Monoclonal Antibody BI 765063, Targeting Myeloid Cells in Immuno-Oncology

OSE Immunotherapeutics SA Announces New European Patent Granted Covering CLEC-1, Novel Myeloid Immune Checkpoint Target for Cancer Immunotherapy

OSE Immunotherapeutics Invited to Present Preclinical Data on its PD-1/IL-7 Bifunctional Program BiCKI®-IL-7 Cancer Immunotherapy

No longer forecast to breakeven

OSE Immunotherapeutics SA to Report Fiscal Year 2021 Results on Mar 30, 2022

Boehringer Ingelheim and OSE Immunotherapeutics to Present Biomarker Analyses From the Phase 1 Clinical Trial With First-in-Class SIRPa Inhibitor BI 765063 in Advanced Solid Tumors

OSE Immunotherapeutics SA Appoints Alexandre Lebeaut as Independent Member of the Board of Directors

OSE Immunotherapeutics SA Announces Acceptance of the US Investigational New Drug Application Obtained by Veloxis Pharmaceuticals, Inc., Its Partner in Transplantation, for CD28 Antagonist VEL-101/FR104

OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use of Tedopi after Failure with PD-1 or PD-L1 Immune Checkpoint Inhibitor Treatment in HLA-A2 Positive Cancer Patients

OSE Immunotherapeutics SA Announce the Continuation of Its Phase 2 Trial Testing Anti-Il-7 Receptor Antagonist OSE-127/S95011 in Ulcerative Colitis After the Interim Futility Analysis

OSE Immunotherapeutics Provides an Update on the First Positive Results and Clinical Development of CoVepiT, Its Multi-Target T-Cell Anti-COVID Vaccine

First half 2021 earnings released: €0.64 loss per share (vs €0.21 loss in 1H 2020)

OSE Immunotherapeutics SA to Present Phase 1 Results with First-In-Class Sirpa Inhibitor Bi 765063 in Advanced Solid Tumors At Esmo 2021

OSE Immunotherapeutics and ARCAGY-GINECO Announce First Patient Randomized in Phase 2 Clinical Trial Evaluating Tedopi in Combination with Pembrolizumab in Ovarian Cancer

Servier and OSE Immunotherapeutics SA Announces Enrollment of First Patient in OSE-127/S95011 Phase 2 Clinical Trial in Sjögren’s Syndrome

OSE Immunotherapeutics SA Announces Voluntary Pause of Enrollment in the CoVepiT Phase 1 Study

Ose Immunotherapeutics and the Fort Foundation Announce Initiation of A Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Opdivo® (Nivolumab) in Non-Small Cell Lung Cancer

OSE Immunotherapeutics Announces Dosing of the First Healthy Volunteer in Phase 1 Clinical Trial of its Multi-Variant Second-Generation COVID-19 Vaccine

OSE Immunotherapeutics SA and Boehringer Ingelheim to Present Positive Phase 1 Results with First-In-Class Sirpa Inhibitor Bi 765063 in Advanced Solid Tumors At Asco 2021